What are the recommended medications for managing withdrawal symptoms from opioid, alcohol, or benzodiazepine (BZD) withdrawal?

Withdrawal Drug Management

Alcohol Withdrawal

Long-acting benzodiazepines (chlordiazepoxide or diazepam) are the gold standard first-line agents for alcohol withdrawal because they provide superior protection against seizures and delirium tremens. 1

Benzodiazepine Selection and Dosing

• Chlordiazepoxide: 25-100 mg orally every 4-6 hours 1
• Diazepam: 5-10 mg orally, intravenously, or intramuscularly every 6-8 hours 1
  • Diazepam has the shortest time to peak effect, facilitating rapid symptom control and accurate titration to avoid over-sedation 2
  • Its long elimination half-life results in gradual self-tapering, producing smoother withdrawal with lower incidence of breakthrough symptoms and rebound phenomena 2
• Lorazepam: Specifically for patients with hepatic dysfunction, advanced age, or serious medical comorbidities, dosed at 1-4 mg every 4-8 hours (initial dose 6-12 mg/day divided) 1

Assessment Tool

• Use the Clinical Institute Withdrawal Assessment for Alcohol (CIWA) protocol to assess severity and guide symptom-triggered benzodiazepine dosing 1, 3
• CIWA-Ar score >8 indicates moderate withdrawal requiring pharmacological treatment 1
• CIWA-Ar score ≥15 indicates severe withdrawal requiring aggressive pharmacological intervention 1

Essential Adjunctive Therapy

• Thiamine 100-300 mg/day is mandatory to prevent Wernicke encephalopathy, maintained for 2-3 months after symptom resolution 1
• Thiamine must be given BEFORE administering IV fluids containing glucose to prevent acute thiamine deficiency 1

Alternative Medications

• Carbamazepine: 200 mg orally every 6-8 hours as an alternative to benzodiazepines, effective in seizure prevention 1
• Haloperidol: 0.5-5 mg orally every 8-12 hours or 2-5 mg intramuscularly as adjunctive therapy for agitation or psychotic symptoms not controlled by benzodiazepines 1

Inpatient Treatment Indications

• Mandatory admission for delirium tremens, withdrawal seizures, and significant alcohol withdrawal syndrome with high CIWA scores 1

---

Opioid Withdrawal

For opioid withdrawal management, buprenorphine or methadone are the medications of choice for medically supervised withdrawal, with symptom-based adjunctive medications for supportive care.

Assessment

• Use the Clinical Opiate Withdrawal Scale (COWS) as the validated comprehensive assessment tool 4
• COWS scoring: 5-12 = mild, 13-24 = moderate, 25-36 = moderately severe, >36 = severe withdrawal 4
• Wait for COWS >13 (moderate withdrawal) before initiating buprenorphine to prevent precipitated withdrawal 5

Buprenorphine Initiation

• Ensure sufficient time has elapsed since last full opioid agonist use before buprenorphine administration to prevent buprenorphine precipitated opioid withdrawal (BPOW) 5
• Risk factors for BPOW include chronic fentanyl use, methadone use, and concurrent benzodiazepine use 5
• If BPOW occurs, treat with additional buprenorphine plus symptom-based supportive care 5

Withdrawal Symptoms

• Physical dependence manifests as: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, mydriasis, irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, increased blood pressure, respiratory rate, or heart rate 6

Critical Monitoring

• Rising respiratory rate and accessory muscle use are objective signs of distress requiring continuous assessment 4
• Monitor pulse rate: 0 points for ≤80 bpm, 1 point for 81-100 bpm, 2 points for 101-120 bpm, 4 points for >120 bpm 4

Important Caution

• Do not rely on specific vital sign thresholds alone to determine treatment needs; clinical context, standardized assessment scores, and objective physical signs must guide management decisions together 4

---

Benzodiazepine Withdrawal

Gradual tapering with careful symptom monitoring is essential for benzodiazepine withdrawal, typically reducing the dose by 25% weekly for short-term users, or more gradually over several weeks to months for long-term users.

Tapering Protocol

• Reduce dose by 25% weekly for short-term users 7
• For long-term users, taper more gradually over several weeks to months 7
• Avoid rigid adherence to a fixed schedule—individual patient response is more important than following a predetermined timeline 7

Critical Warning

• Abrupt discontinuation or rapid dosage reduction can precipitate acute withdrawal reactions, including seizures, which can be life-threatening 7

Adjunctive Treatments

• Consider carbamazepine, pregabalin, paroxetine, or magnesium aspartate to facilitate tapering, though evidence is limited 7
• Be cautious as adjunctive medications may require their own tapering schedules 7

Non-Pharmacological Interventions

• Cognitive-behavioral therapy, supportive psychotherapy, relaxation techniques, and patient education about withdrawal symptoms 7

Symptom Management

• Use a standardized scoring system to assess withdrawal symptoms 7
• For breakthrough anxiety or agitation, use the same benzodiazepine at the lowest effective dose rather than adding a different medication 7

Patient Education

• Educate patients about benzodiazepine risks and benefits of tapering, as this approach has shown success in facilitating withdrawal 7